In summary, the data presented by Yan et al (2018) define a mechanism‐based targeting of HDAC3 upstream of two key genomic altered pathways in prostate cancer and provide preclinical proof of principle to guide inhibitor development toward the clinic. Here, HDAC3 is linked to Familial prostate cancer.